.
. [9] .
Mechanistic studies of microRNAs have met challenges that are not encountered during the functional dissection of translated genes. This stems from the relative promiscuity of microRNA-dependent gene targeting, characterized by tens or even hundreds of predicted targets, with only partial overlap between the various prediction programs (PicTar, TargetScan, Miranda, etc.). A major step forward has been constituted by the development of animal models that open the way for in vivo investigation of microRNA roles in physiology and pathology. For example, the first transgenic mouse overexpressing miR-155 in B-lymphocytes turned out to be a powerful model of haematological malignancies that naturally overexpress this microRNA (Hodgkin lymphomas, B cell and Burkitt lymphomas) [8]. Conversely, mir-155 gene knockouts developed a wide dysfunction of the immune response, involving T, B and dendritic cells
The involvement of microRNAs in disorders that sit at the top of morbidity and mortality lists (cancer, inflammation, and possibly, cardiovascular pathology and stroke [10] ) can be viewed as an opportunity for novel therapeutic approaches. Along these lines, progress has been achieved for the targeting of select disease-relevant microRNAs, with several drug candidates making promising strides in clinical trials [11] .
The plethora of exciting developments in the microRNA field, from basic science to translational applications, serve as fertile background for the review series hosted by the Journal of Cellular and Molecular Medicine. It is also an opportunity to wholeheartedly invite researchers from the field and beyond to contribute to the journal with novel angles to this fast-evolving area.
